Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan + dapagliflozin vs dapagliflozin vs placebo in cirrhosis with portal hypertension (Phase IIa/b)
2021-006577-30Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis and Portal Hypertension (PH) comparing zibotentan + dapagliflozin, dapagliflozin monotherapy and placebo (3 arms). Primary endpoint: Part A Primary End Point. Started Jul 2022; status: active.
02
Drugs
dapagliflozinzibotentan
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2021-006577-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006577-30.